<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: March 31, 2000
(Date of earliest event reported)
AVANIR PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
9393 Towne Centre Drive, Suite 200, San Diego, California 92121
(Address of principal executive offices) (Zip code)
(858) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
License Agreement with SmithKline Beecham
On March 31, 2000, we signed an exclusive license agreement with
SmithKline Beecham ("SKB"), to allow SKB to market our docosanol 10% cream as an
over the counter treatment for cold sores in the United States and Canada.
Under the terms of the license agreement, SmithKline Beecham Consumer
Healthcare will be responsible for all sales and marketing activities and the
manufacturing and distribution of docosanol 10% cream. Docosanol 10% cream is
currently under review by the U.S. Food and Drug Administration ("FDA") and, if
approved, will be the first over the counter product in the cold sore treatment
category with FDA approval.
The terms of the license agreement provide for our company to receive
license fees and milestone payments up to $25 million, subject to achievement of
certain milestones. The majority of the milestone payments are structured around
obtaining FDA approval of our new drug application and product launch. A final
portion of the payments is structured around achieving a sales performance
milestone within 12 months of product launch. In addition, we will receive
royalties for sales of docosanol 10% cream. A small portion of the $25 million
was due upon signing the license agreement and has been paid and is
nonrefundable. However, we will not receive the balance of milestone payments or
the royalties if the FDA does not approve the use of docosanol 10% cream for
sale over the counter as a treatment for cold sores. We believe the FDA's
internal review guidelines may allow the Agency until Monday, June 5, 2000 to
make a decision on our new drug application.
In November 1999, the FDA informed us that our clinical data for
docosanol 10% cream would be sufficient for approval as an over the counter
product, provided that the FDA finds no serious discrepancies from a site audit
conducted at a clinical study site in The Netherlands and that agreement can be
reached with the Agency on labeling of the product for the over the counter
market. The clinical study in The Netherlands was conducted in 1992-1993 by our
European partner Yamanouchi Europe under our investigational new drug
application. We have submitted final responses to all FDA questions about our
new drug application along with proposed consumer product labeling. We are
unaware of any other matters at this time that the FDA must still evaluate in
order to make a decision on our new drug application.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
10.1+ License Agreement, dated as of March 31, 2000, by and between
AVANIR Pharmaceuticals, a California corporation, and SB
Pharmco Puerto Rico Inc., a Puerto Rico corporation.
99.1 Press release dated April 3, 2000.
- -----
+ Confidential Treatment will be requested with respect to certain portions of
this exhibit. Omitted portions will be filed separately with the Securities
and Exchange Commission.
1
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
AVANIR PHARMACEUTICALS
Date: May 4, 2000 By: /s/ GREGORY P. HANSON
-----------------------------------
Gregory P. Hanson
Vice President, Finance and
Chief Financial Officer
2
<PAGE> 1
*** Indicates text was omitted and filed separately. Confidential treatment
requested under SEC Rule 80(b)(4), 17 C.F.R. Section 200.80(b)(4).
EXHIBIT 10.1
CONFIDENTIAL TREATMENT REQUESTED
LICENSE AGREEMENT
BETWEEN
SB PHARMCO PUERTO RICO INC.
AND
AVANIR PHARMACEUTICALS
1
<PAGE> 2
CONFIDENTIAL TREATMENT REQUESTED
LICENSE AGREEMENT
THIS LICENSE AGREEMENT (hereinafter "AGREEMENT"), made as of the 31st day of
March, 2000 between SB PHARMCO PUERTO RICO INC., a corporation of the territory
of Puerto Rico having a principal place of business at Road 172, Rm9.1/Bo.,
Certenejas, Cidra Puerto Rico 00639 and AVANIR PHARMACEUTICALS, a corporation of
the state of California, having a principal place of business at 9393 Towne
Centre Drive, Suite 200, San Diego, California 92121.
WITNESSETH THAT:
WHEREAS, AVANIR, as defined below, is the owner of all right, title and
interest in certain patents, identified in Appendix A hereto, and know-how
relating to a compound known as docosanol; and
WHEREAS, SB, as defined below, desires to obtain certain licenses in
certain countries of the world from AVANIR to develop and commercialize
docosanol in such countries under the aforesaid patents and know-how, and AVANIR
is willing to grant to SB such licenses;
NOW, THEREFORE, in consideration of the covenants and obligations
expressed herein, and intending to be legally bound, and otherwise to be bound
by proper and reasonable conduct, the parties agree as follows:
1. DEFINITIONS
1.01 "AFFILIATES" shall mean any corporation, firm, partnership or other
entity, whether de jure or de facto, which directly or indirectly owns, is owned
by or is under common ownership with a party to this AGREEMENT to the extent of
at least fifty percent (50%) of the equity (or such lesser percentage which is
the maximum allowed to be owned by a foreign corporation in a particular
jurisdiction) having the power to vote on or direct the affairs of the
1
<PAGE> 3
CONFIDENTIAL TREATMENT REQUESTED
entity and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with such party.
1.02 "AVANIR" shall mean Avanir Pharmaceuticals, a corporation of the
state of California, having a principal place of business at 9393 Towne Centre
Drive, Suite 200, San Diego, California 92121.
1.03 "AVANIR FIELD" shall mean (i) the prescription use of PRODUCT in
the USA, or (ii) the NON-PRESCRIPTION USE of PRODUCT permitted by a regulatory
approval received by AVANIR from a competent regulatory authority after the date
of the OTC Approval (as defined in Paragraph 3.01(4)) (a "Later Approval")
authorizing the switch of a former prescription use of PRODUCT, *** to a
NON-PRESCRIPTION USE of PRODUCT provided always that such NON-PRESCRIPTION USE
of PRODUCT as permitted by such regulatory approval received by AVANIR may be
excluded from the AVANIR FIELD ***.
1.04 "EFFECTIVE DATE" shall mean the date upon which this AGREEMENT is
effective and shall be the date of this AGREEMENT first written above.
1.05 "FIELD" shall mean (i) the NON-PRESCRIPTION USE of PRODUCT in
humans, or (ii) in Canada, the prescription use of PRODUCT in humans during the
time that SB intends to seek or is seeking marketing approval from a competent
regulatory authority to switch such prescription use to a NON PRESCRIPTION USE.
FIELD shall not include AVANIR FIELD.
1.06 "FORCE MAJEURE EVENT" shall mean any circumstances beyond the
reasonable control of SB or AVANIR including, but not limited to, government
legislation, fires, floods, explosions, epidemics, accidents, acts of God, wars
or riots, labor disputes or lockouts, or any order, agreement or direction or
any likely order, agreement or direction with or by any governmental agency that
directly prevents or, at SB's reasonable determination, is likely to directly
prevent the launch of PRODUCT by SB.
2
<PAGE> 4
CONFIDENTIAL TREATMENT REQUESTED
1.07 "KNOW-HOW" shall mean all present and future technical information
and know-how in the FIELD which relates to PRODUCT and shall include, without
limitation, all biological, chemical, pharmacological, toxicological, clinical,
assay, control and manufacturing data and any other information relating to
PRODUCT and useful for the development and commercialization of PRODUCT.
1.08 "NET SALES" shall mean the gross receipts representing sales of
PRODUCT in the TERRITORY under this AGREEMENT by SB, its AFFILIATES or its/their
PERMITTED SUBLICENSEES ("the Selling Party") to THIRD PARTIES in finished
product form (i.e., packaged and labeled for sale to the ultimate consumer) less
deductions for:
(i) transportation charges, including insurance, for transporting
PRODUCT;
(ii) trade, quantity and cash discounts allowed on PRODUCT; and
(iii) allowances or credits to customers on account of rejection or
return of PRODUCT.
Sales between SB, its AFFILIATES and its or their PERMITTED SUBLICENSEES shall
be excluded from the computation of NET SALES and no royalties will be payable
on such sales.
1.09 "NON-PRESCRIPTION USE" shall mean that a prescription from a
physician or other health care professional is not required by the regulatory
authorities in a country in which PRODUCT is purchased to enable consumers to
purchase PRODUCT.
1.10 "PERMITTED SUBLICENSEES" shall mean THIRD PARTIES which have
entered into arrangements with SB or its AFFILIATES for the co-promotion or
co-marketing of PRODUCT as a means to augment SB's efforts in the
commercialization of PRODUCT, or other THIRD PARTIES in respect of which AVANIR
has given its prior written consent, such consent not to be unreasonably
withheld or delayed.
3
<PAGE> 5
CONFIDENTIAL TREATMENT REQUESTED
1.11 "PATENTS" shall mean all patents and patent applications in the
FIELD which are or become owned by AVANIR, or to which AVANIR otherwise has, now
or in the future, the right to grant licenses, which generically or specifically
claim PRODUCT, a process for manufacturing or formulating PRODUCT, an
intermediate used in such process or a use of PRODUCT in the FIELD. Included
within the definition of PATENTS are all continuations, continuations-in-part,
divisions, patents of addition, reissues, renewals or extensions thereof. Also
included within the definition of PATENTS are any patents or patent applications
which generically or specifically claim any improvements on PRODUCT or
intermediates or manufacturing processes required or useful for production of
PRODUCT which are developed by AVANIR, or which AVANIR otherwise has the right
to grant licenses, now or in the future, during the term of this AGREEMENT. The
current list of patent applications and patents encompassed within PATENTS is
set forth in Appendix A attached hereto.
1.12 "PRODUCT" shall mean a medicinal product including as an ingredient
the chemical compound known as docosanol, whose more specific chemical formula
is CH3 (CH2)20 - CH2OH and other aliphatic saturated straight chain monohydric
alcohols of chain length C20 - C28, its prodrugs and metabolites, and all
esters, salts, hydrates, solvates, polymorphs and isomers thereof, and shall
include compositions comprising such compound, prodrug or metabolites, or
esters, salts, hydrates, solvates, polymorphs and isomers or any product, the
manufacture, use, sale or import of which, but for the license granted under
this Agreement, infringes any PATENT or employs any KNOW-HOW in the FIELD.
1.13 "SB" shall mean SB Pharmco Puerto Rico Inc., a corporation of the
territory of Puerto Rico, having its principal place of business at Road 172, Rm
9.1/Bo., Certenejas, Cidra Puerto Rico 00639.
1.14 "TERRITORY" shall mean the USA and Canada. For the avoidance of
doubt, the parties agree that the "ship to" address of any THIRD PARTY will
determine whether such THIRD PARTY is in the TERRITORY.
4
<PAGE> 6
CONFIDENTIAL TREATMENT REQUESTED
1.15 "THIRD PARTY(IES)" shall mean any party other than SB, AVANIR and
their respective AFFILIATES.
1.16 "USA" shall mean the United States of America, including all of its
territories and possessions (including, but without limitation, Puerto Rico).
2. GRANT, FIRST RIGHT TO NEGOTIATE AND OPTION
2.01 AVANIR hereby grants to SB an exclusive license with the right to
grant sublicenses to its AFFILIATES and PERMITTED SUBLICENSEES under PATENTS and
KNOW-HOW to make, have made, use, sell, offer for sale, and import PRODUCT, in
the FIELD, in the TERRITORY, subject to the other terms and conditions of this
AGREEMENT and as limited by the AVANIR FIELD. The rights to make, have made,
use, sell, offer for sale and import shall include all activities concerning the
subject matter of PATENTS and KNOW-HOW which activities would, but for the
license herein granted, infringe AVANIR's intellectual property rights under
PATENTS or KNOW-HOW.
2.02 AVANIR shall not seek customers in the FIELD and TERRITORY and will
not maintain a distribution depot in the TERRITORY for sales of PRODUCT to
customers in the FIELD and TERRITORY. Notwithstanding the foregoing, AVANIR
shall be entitled to manufacture PRODUCT in the TERRITORY for the sole purpose
of exporting PRODUCT outside of the TERRITORY provided that AVANIR shall not
sell or supply PRODUCT to any THIRD PARTY in the event that AVANIR believes or
has reasonable cause to believe that such THIRD PARTY intends to sell such
PRODUCT into the TERRITORY and FIELD. SB shall not seek customers outside the
TERRITORY or FIELD and will not maintain a distribution depot outside the
TERRITORY for sales of PRODUCT to customers outside the TERRITORY or FIELD.
Notwithstanding the foregoing, SB shall be entitled to manufacture PRODUCT
outside the TERRITORY for the sole purpose of exporting PRODUCT into the
TERRITORY provided that SB shall not sell or supply PRODUCT to any THIRD PARTY
in the event that SB believes
5
<PAGE> 7
CONFIDENTIAL TREATMENT REQUESTED
or has reasonable cause to believe that such THIRD PARTY intends to sell such
PRODUCT outside the FIELD or TERRITORY.
2.03 AVANIR hereby grants to SB an exclusive option to enter into an
agreement with AVANIR for the exclusive right to make, have made, use, sell,
offer for sale, and import PRODUCT, in the FIELD, in additional countries
(excluding South Korea and Israel) outside the TERRITORY ("Exclusive Option").
*** Promptly after SB's written request during the Exclusive Option Period, SB
and AVANIR shall negotiate in good faith, taking into account the reasonable
commercial potential of PRODUCT in such country(ies), the terms and conditions
under which AVANIR shall grant SB exclusive rights under AVANIR's patent and
know-how rights in such country(ies) to make, have made, use, sell, offer for
sale and import PRODUCT in such country(ies), to the extent that AVANIR is
legally able to do so. *** The term `Exclusive Option Period' shall mean that
AVANIR will not, directly or indirectly, permit its directors, AFFILIATES,
representatives or agents to do any of the following: negotiate, undertake,
authorize, recommend, propose or enter into any transaction involving the
PATENTS and KNOW HOW in the FIELD ("Competing Transaction"); or facilitate,
encourage, solicit or initiate or in any way engage in any discussion,
negotiation or submission of a proposal or offer in respect of a Competing
Transaction; or furnish or cause to be furnished to any THIRD PARTY any
information concerning the PATENTS and KNOW HOW in connection with a Competing
Transaction; or otherwise cooperate in any way with or assist or participate in,
facilitate or encourage, any effort or attempt by any THIRD PARTY to do or seek
any of the foregoing. It is agreed that during the Exclusive Option Period
AVANIR will be entitled to utilize THIRD PARTY consultants to assist AVANIR with
an evaluation of the potential to commercialize PRODUCT in countries outside the
TERRITORY and that such interaction will not be considered to be a Competing
Transaction as defined in this Paragraph 2.03. Further, SB shall notify AVANIR
promptly in the event that SB decides that it does not wish to commercialize
PRODUCT in a particular country in which case AVANIR shall be free to negotiate
and enter into a Competing Transaction in respect of such country,
notwithstanding
6
<PAGE> 8
CONFIDENTIAL TREATMENT REQUESTED
that the Exclusive Option shall apply to all other countries outside the
TERRITORY during the Exclusive Option Period.
2.04 AVANIR hereby grants to SB the first right to negotiate with AVANIR
to obtain an exclusive license, with the right to grant sublicenses to
AFFILIATES and PERMITTED SUBLICENSEES, under PATENTS and KNOW-HOW owned or
controlled by AVANIR to make, have made, use, sell, offer for sale, and import
PRODUCT for NON-PRESCRIPTION USE resulting directly from a Later Approval (as
defined in Paragraph 1.03) in the TERRITORY, upon terms to be mutually
negotiated by the parties in good faith. ***
3. PAYMENTS AND ROYALTIES
3.01 In consideration for SB's acquisition of exclusive rights under the
license concerning PATENTS and KNOW-HOW granted to SB in this AGREEMENT, SB
shall make the following payments to AVANIR, up to a maximum of twenty five
million US dollars (US$25,000,000) (exclusive of royalty payments) in respect
of the license grant to SB related to USA and Canada in the specified
incremental amounts, within ten (10) days after the occurrence of the milestones
set out in Paragraph 3.01(a) and 3.01(b) and within thirty (30) days after the
occurrence of the milestones set out in Paragraph 3.01(c), 3.01(d) and 3.01(e):
***
provided that:
(1) each such payment shall be subject to the terms of Paragraph 11.01
and shall be made only one time regardless of how many times such milestones are
achieved and regardless of how many PRODUCTS achieve such milestones, and no
payment shall be owed for a milestone which is not reached;
(2) ***
(3) each such payment shall be non-refundable and non-creditable to SB;
7
<PAGE> 9
CONFIDENTIAL TREATMENT REQUESTED
(4)
***
3.02 As further consideration for the license under PATENTS and KNOW-HOW
granted to SB under this AGREEMENT, SB shall pay AVANIR
***
3.04 SB's Patent Royalty obligations under Paragraph 3.02 shall become
effective in each country of the TERRITORY at such time as an issued and valid
PATENT is granted in such country claiming the PRODUCT sold. SB's Patent Royalty
obligations under Paragraph 3.02 will expire on a country by country basis upon
the expiration of the last remaining valid PATENT claiming the PRODUCT sold in
such country provided that such Patent Royalty obligations shall be subject, in
any event, to the provisions of Paragraph 3.05 to 3.07. Notwithstanding any
other provisions set out in this Paragraph 3.04, SB shall have no further
liability or obligation to make further Patent or Non-Patent Royalty payments to
AVANIR with respect to the TERRITORY after the later of ***
3.05 In the event that any THIRD PARTY initiates any legal or
administrative proceeding challenging the validity, scope or enforceability of
all PATENT(S) claiming PRODUCT sold on the date of such a challenge in any
particular country of the TERRITORY, then the royalty obligation under Paragraph
3.02 in such country shall be amended during such challenge period *** If the
validity and enforceability of (i) any individual PATENTS claiming the PRODUCT
sold in such particular country is upheld by a court or other legal or
administrative tribunal from which no appeal is or can be taken, then SB and
AVANIR shall instruct the escrow agent to pay the Escrow
8
<PAGE> 10
CONFIDENTIAL TREATMENT REQUESTED
Payment plus all interest accruing to such Escrow Payment to AVANIR, or (ii) all
PATENTS claiming the PRODUCT sold in such particular country are not upheld by a
court or other legal or administrative tribunal from which no appeal is or can
be taken, then SB and AVANIR shall instruct the escrow agent to pay the Escrow
Payment plus all interest accruing to such Escrow Payment to SB less the costs
incurred in instructing the escrow agent concerned. In the event that the
validity and enforceability of all the PATENT(S) claiming the PRODUCT sold in a
particular country are not upheld by such court or other legal or administrative
tribunal, then SB shall retain the license granted herein in such country but
the future royalty to be paid by SB to AVANIR shall be limited to the Non-Patent
Royalty (as defined in Paragraph 3.02) for the remaining term of this AGREEMENT.
***
3.07 Any filing, maintenance or prosecution costs (which shall include
any costs incurred by SB in exercising its rights under Paragraph 7.04) related
to PATENTS (which for the avoidance of doubt excludes patents solely or jointly
owned by SB) and which are incurred by SB under this Agreement shall be fully
creditable against any payments owed to AVANIR by SB under this Agreement.
3.08 Any issued patent is valid until invalidated. Invalidation shall
mean a decision of a court of other governmental agency of competent
jurisdiction, unappealable or not appealed within the time allowed for appeal,
that all claims covering the PRODUCT in an unexpired PATENT are invalid or
unenforceable.
3.09 All Supply Overage Payments (as defined in Paragraph 15.02) due and
payable by AVANIR to SB under Paragraph 15.02 shall be fully creditable against
any royalty payments owed to AVANIR by SB under this Agreement.
4. COMPULSORY LICENSES AND THIRD PARTY LICENSES
4.01 In the event that a governmental agency in any country or territory
grants or compels AVANIR to grant a license to any THIRD PARTY for PRODUCT, SB
shall have the benefit in such country or territory of the terms granted to such
THIRD PARTY to the extent that such terms are more favorable taken as a whole
than those of this AGREEMENT.
9
<PAGE> 11
CONFIDENTIAL TREATMENT REQUESTED
4.02 If, during the term of this AGREEMENT, SB deems it necessary to
seek, exercise or execute a license from any THIRD PARTY in order to avoid
infringement during the exercise of the license herein granted, fifty percent
(50%) of any royalties or other fees paid to such THIRD PARTY under such license
("THIRD PARTY Fee") may be deducted from royalties otherwise due to AVANIR under
this AGREEMENT; provided that in no event shall the Patent Royalty paid to
AVANIR by SB be reduced below fifty percent (50%) of what would otherwise have
been paid by SB in the absence of such a THIRD PARTY license, and provided
further that SB shall be entitled to carry forward for the remainder of this
AGREEMENT any excess deduction to be fully credited against future SB royalty
payments to AVANIR until the full deduction of the THIRD PARTY Fee has been
effected. Prior to the commencement of SB crediting the THIRD PARTY Fee against
royalty payments made by SB to AVANIR, SB shall notify AVANIR of its intention
to seek or exercise or execute a license with a THIRD PARTY. In the event that
AVANIR believes that such a THIRD PARTY license is not required to avoid
infringement of THIRD PARTY patents, then AVANIR shall so notify SB in writing,
and the parties shall promptly submit such issue thereafter to a mutually
acceptable THIRD PARTY who has suitable expertise on the topic in question
("Unaffiliated Expert"), such Unaffiliated Expert to be chosen by SB and AVANIR
within ten (10) business days after AVANIR's notification. SB and AVANIR shall
request resolution within thirty (30) days after the date of such submission to
such Unaffiliated Expert, and SB shall be entitled to deduct the THIRD PARTY Fee
during the period of time that the Unaffiliated Expert is making a resolution of
the matter. The resolution of the Unaffiliated Expert shall be binding on both
SB and AVANIR. In the event that the Unaffiliated Expert resolves that such a
THIRD PARTY license is necessary to avoid infringement of THIRD PARTY patents,
then the costs of engaging such Unaffiliated Expert shall be borne by AVANIR. In
the event that the Unaffiliated Expert resolves that such a THIRD PARTY license
is not necessary to avoid infringement of THIRD PARTY patents, then the costs of
engaging such Unaffiliated Expert shall be borne by SB, any THIRD PARTY Fee
pertaining to the THIRD PARTY license in question and credited against royalty
payments made by SB to AVANIR shall be refunded in full to AVANIR and no further
deductions of the THIRD PARTY Fee shall be made by SB in respect of such THIRD
PARTY license.
10
<PAGE> 12
CONFIDENTIAL TREATMENT REQUESTED
5. DEVELOPMENT OF PRODUCT
5.01 As of the EFFECTIVE DATE, and during the term of the AGREEMENT, SB
shall have full control and authority, with full responsibility, subject to the
provisions of Article 5, over research, development, registration and
commercialization of PRODUCT in the FIELD and in the TERRITORY, and all such
activity shall be undertaken at SB's expense. SB will exercise its reasonable
efforts and diligence in developing and commercializing PRODUCT in accordance
with its business, legal, medical and scientific judgement and in undertaking
investigations and actions required to obtain appropriate governmental approvals
to market PRODUCT in the FIELD and in the TERRITORY. It is agreed that AVANIR
will control (unless and until otherwise notified by SB) for and on behalf of
SB, and at SB's expense, the obtaining of all necessary government approvals to
market PRODUCT in the FIELD in Canada, such approvals to be transferred to SB as
soon as reasonably practicable after AVANIR's receipt thereof. SB will undertake
the levels of marketing as set forth on Appendix C.
5.02 (a) SB shall keep AVANIR informed of the progress of SB's efforts
to develop and commercialize PRODUCT on a quarterly basis for the first two
years of this AGREEMENT and semi-annually thereafter. Furthermore, at AVANIR's
option, SB and AVANIR shall meet in person for every other required progress
report
(b) AVANIR shall provide SB with summaries of all protocols in
respect of preclinical and clinical studies concerning PRODUCT inside the FIELD
outside the TERRITORY and all studies outside the FIELD concerning topical and /
or mucosal application of PRODUCT *** to be conducted by AVANIR, its
sublicensees or other THIRD PARTIES acting on behalf of AVANIR subject to
AVANIR's obligation of confidentiality to its sublicensees.
***
5.03 AVANIR shall provide to SB, at SB's request and expense, technical
assistance within its area of expertise concerning development, registration,
production and commercialization of PRODUCT. Provision of such technical
assistance shall include, but not
11
<PAGE> 13
CONFIDENTIAL TREATMENT REQUESTED
be limited to, visits by AVANIR personnel to SB, at SB's expense, and visits by
SB personnel to AVANIR, at SB's expense, at times and for periods of time upon
which the parties will agree, and supply of any KNOW-HOW that SB may require.
5.04 Within three (3) days after receiving SB's written request, AVANIR
shall provide SB with a letter addressed to FDA authorizing and requesting that
the NDA owned by AVANIR and pertaining to PRODUCT in the TERRITORY be
transferred, in its entirety, to the name of SB, or its AFFILIATE, as SB may
elect. AVANIR shall provide SB with a copy of the letter and SB shall
immediately send a letter to FDA accepting the NDA. AVANIR will be entitled to
copy and reference the NDA outside the FIELD and inside the FIELD if outside the
TERRITORY freely as it determines. Each party will notify the other immediately
by telephone (with prompt written follow-up) of any inquiry, contact or
communication received from any governmental regulatory agency or other official
body (within or outside of the TERRITORY) which relates to the PRODUCT or any
component or ingredient thereof, and will promptly furnish the other party with
copies of all written communications relating thereto sent to or received from
such regulatory agency.
5.05 A "Steering Committee" shall be created to monitor the development
and commercialization of the PRODUCT in the FIELD in the TERRITORY. The Steering
Committee shall consist of five voting members, with AVANIR having the right to
designate two voting members and SB having the right to designate the three
remaining voting members. The chairperson of the Steering Committee shall be
designated by SB from among those members of the Steering Committee appointed by
SB. The Steering Committee shall meet no less frequently than once each calendar
quarter. The chairperson of the Steering Committee may call special meetings of
the Steering committee from time-to-time. The duties of the Steering Committee
shall consist of overseeing the development and commercialization of the PRODUCT
in the FIELD in the TERRITORY, preliminarily mediating disputes, confirming
attainment of milestones and discussing the worldwide development of PRODUCT.
The decisions of the STEERING Committee shall be based upon the majority vote of
the voting members thereof. The purpose of Steering Committee meetings shall be
to review results, monitor and audit the
12
<PAGE> 14
CONFIDENTIAL TREATMENT REQUESTED
progress of the development and commercialization of the PRODUCT in the FIELD in
the TERRITORY and confirm the accomplishment of milestones. Quarterly
developmental progress reports, or at such other intervals as shall be deemed
appropriate by the Steering Committee, will be delivered by each party to the
other, consistent with each party's respective roles, no later than seven
business days after the conclusion of the applicable reporting period.
6. EXCHANGE OF INFORMATION AND CONFIDENTIALITY
6.01 Promptly after the EFFECTIVE DATE, AVANIR shall disclose and supply
to SB all KNOW-HOW within AVANIR's possession which was not already supplied to
SB prior to the EFFECTIVE DATE. Thereafter, AVANIR shall promptly disclose and
supply to SB any further KNOW-HOW that may become known to AVANIR.
6.02 During the term of this AGREEMENT and for five (5) years
thereafter, irrespective of any termination earlier than the expiration of the
term of this AGREEMENT, AVANIR and SB shall not use or reveal or disclose to
THIRD PARTIES any confidential information received from the other party or
otherwise developed by either party in the performance of activities in
furtherance of this AGREEMENT without first obtaining the written consent of the
disclosing party, except as may be otherwise provided herein, or as may be
required for purposes of investigating, developing, manufacturing or marketing
PRODUCT or for securing essential or desirable authorizations, privileges or
rights from governmental agencies, or is required to be disclosed to a
governmental agency or is necessary to file or prosecute patent applications
concerning PRODUCT or to carry out any litigation concerning PRODUCT. This
confidentiality obligation shall not apply to such information which is or
becomes a matter of public knowledge, or is already in the possession of the
receiving party, or is disclosed to the receiving party by a THIRD PARTY having
the right to do so, or is subsequently and independently developed by employees
of the receiving party or AFFILIATES thereof who had no actual knowledge of the
confidential information disclosed, or is required by law to be disclosed. The
parties shall take reasonable measures to assure that no unauthorized use or
disclosure is made by others to whom access to such information is granted.
13
<PAGE> 15
CONFIDENTIAL TREATMENT REQUESTED
6.03 Nothing herein shall be construed as preventing SB from disclosing
any information received from AVANIR hereunder to an AFFILIATE, PERMITTED
SUBLICENSEE or distributor of SB in furtherance of the objectives and
obligations of the parties under this AGREEMENT, provided, in the case of a
PERMITTED SUBLICENSEE or distributor, such PERMITTED SUBLICENSEE or distributor
has undertaken a similar obligation of confidentiality with respect to the
confidential information. Nothing herein shall be construed as preventing AVANIR
from disclosing any information received from SB hereunder to an AFFILIATE,
banker, investor or distributor of AVANIR, provided, in the case of a banker,
investor or distributor, such banker, investor or distributor has undertaken a
similar obligation of confidentiality with respect to the confidential
information. In no event shall AVANIR be permitted to disclose any confidential
information received from SB hereunder to a sublicensee of AVANIR or to any
other THIRD PARTY without obtaining SB's prior consent.
6.04 All confidential information disclosed by one party to the other
shall remain the intellectual property of the disclosing party. In the event
that a court or other legal or administrative tribunal, directly or through an
appointed master, trustee or receiver, assumes partial or complete control over
the assets of a party to this AGREEMENT based on the insolvency or bankruptcy of
such party, the bankrupt or insolvent party shall promptly notify the court or
other tribunal (i) that confidential information received from the other party
under this AGREEMENT remains the property of the other party and (ii) of the
confidentiality obligations under this AGREEMENT. In addition, the bankrupt or
insolvent party shall, to the extent permitted by law, take all steps necessary
or desirable to maintain the confidentiality of the other party's confidential
information and to ensure that the court, other tribunal or appointee maintains
such information in confidence in accordance with the terms of this AGREEMENT.
6.05 No public announcement or other disclosure to THIRD PARTIES
concerning the OTC Approval or the existence of or terms of this AGREEMENT shall
be made, either directly or indirectly, by any party to this AGREEMENT, except
and to the extent that such disclosure may be legally required or as may be
required for recording purposes, without first obtaining the approval of the
other party, not to be unreasonably withheld or delayed, and agreement upon the
14
<PAGE> 16
CONFIDENTIAL TREATMENT REQUESTED
nature and text of such announcement or disclosure. The party desiring to make
any such public announcement or other disclosure shall inform the other party of
the proposed announcement or disclosure at least three (3) business days prior
to public release, and shall provide the other party with a written copy
thereof, in order to allow such other party to comment upon such announcement or
disclosure. Each party agrees that it shall cooperate fully with the other with
respect to all disclosures regarding this AGREEMENT to the Securities Exchange
Commission and any other governmental or regulatory agencies, including requests
for confidential treatment of proprietary information of either party included
in any such disclosure.
6.06 AVANIR shall not submit for written or oral publication any
manuscript, abstract or other publication which includes data or other
information generated and provided by SB without first obtaining the prior
written consent of SB. Further, AVANIR shall submit for SB's review, comment and
consent any other manuscript, abstract or the like relating to the PRODUCT no
later than thirty (30) days prior to AVANIR's submission of the same for
publication. In the event that SB declines to consent, such consent not to be
unreasonably withheld or delayed, to the publication of the same on the basis
that publication will or may damage SB's commercialization of PRODUCT in the
FIELD in the TERRITORY, then AVANIR may, in the event that AVANIR believes that
such studies will not and are not likely to damage SB's commercialization of
PRODUCT in the FIELD in the TERRITORY, so notify SB in writing, and the parties
shall promptly submit such issue thereafter to a mutually acceptable THIRD PARTY
who has suitable expertise on the topic in question ("Unaffiliated Expert"),
such Unaffiliated Expert to be chosen by SB and AVANIR within ten (10) business
days after AVANIR's notification. SB and AVANIR shall request resolution within
thirty (30) days after the date of such submission to such Unaffiliated Expert,
and AVANIR shall not submit for written or oral publication such manuscript,
abstract or other publication during the period of time that the Unaffiliated
Expert is making a resolution of the matter. The resolution of the Unaffiliated
Expert shall be binding on both SB and AVANIR. In the event that the
Unaffiliated Expert resolves that publication will or may damage SB's
commercialization of PRODUCT in the FIELD in the TERRITORY, then the costs of
engaging such Unaffiliated Expert shall be borne by AVANIR. In the event that
the Unaffiliated Expert resolves that publication will not or
15
<PAGE> 17
CONFIDENTIAL TREATMENT REQUESTED
is unlikely to damage SB's commercialization of PRODUCT in the FIELD in the
TERRITORY, then the costs of engaging such Unaffiliated Expert shall be borne by
SB and AVANIR shall be free to submit the said manuscript, abstract or other
publication for written or oral publication.
6.07 AVANIR shall not submit the manuscript, abstract or the like for
publication until AVANIR has received SB's prior consent to publish the same or
until the Unaffiliated Expert has resolved that such publication will not or is
unlikely to damage SB's commercialization of the PRODUCT in the FIELD in the
TERRITORY. AVANIR shall use its diligent efforts to bind the clinical
investigators and other agents it utilizes for the development of PRODUCT to a
provision similar to this Paragraph, provided that it is understood that
AVANIR's inability to bind a clinical investigator to such a similar provision
shall not prohibit AVANIR from utilizing such clinical investigator.
6.08 SB's contribution shall be noted in all publications or
presentations by acknowledgment or coauthorship, where appropriate.
6.09 Nothing in this AGREEMENT shall be construed as preventing or in
any way inhibiting either party from complying with statutory and regulatory
requirements governing the development, manufacture, use and sale or other
distribution of PRODUCT in any manner which it reasonably deems appropriate,
including, for example, by disclosing to regulatory authorities confidential or
other information received from the other party or THIRD PARTIES.
6.10 The reporting of adverse events related to PRODUCT to regulatory
authorities in the TERRITORY shall be performed in accordance with the
pharmacovigilance agreement attached to this AGREEMENT as Appendix B.
7. PATENT PROSECUTION AND LITIGATION
7.01 Each party shall have and retain sole and exclusive title to all
inventions, discoveries and know-how which are made, conceived, reduced to
practice or generated by its employees, agents, or other persons acting under
its authority in the course of or as a result of this AGREEMENT. Each party
shall own a fifty percent (50%) undivided interest in all such
16
<PAGE> 18
CONFIDENTIAL TREATMENT REQUESTED
inventions, discoveries and know-how made, conceived, reduced to practice or
generated jointly by employees, agents, or other persons acting under the
authority of both parties in the course of or as a result of this AGREEMENT.
Except as expressly provided in this AGREEMENT, each joint owner may make, use,
sell, keep, license, assign, or mortgage such jointly owned inventions,
discoveries and know-how, and otherwise undertake all activities a sole owner
might undertake with respect to such inventions, discoveries and know-how,
without the consent of and without accounting to the other joint owner.
7.02 Each party shall promptly notify the other upon the making,
conceiving or reducing to practice of any invention or discovery under Paragraph
7.01 concerning PRODUCT. With respect to any such invention,
(i) SB shall have the first right, using in-house or
outside legal counsel selected at SB's sole discretion, to prepare, file,
prosecute, maintain and extend patent applications and patents concerning all
such inventions and discoveries related to PRODUCT owned in whole by SB or
jointly by SB and AVANIR with appropriate credit to AVANIR's representatives,
including the naming of such parties as inventors where appropriate and in
accordance with the relevant legal requirements, for which SB shall bear the
costs. SB shall solicit AVANIR's' advice and review of the nature and text of
such patent applications and important prosecution matters related thereto in
reasonably sufficient time prior to filing thereof, and SB shall take into
account AVANIR's reasonable comments related thereto.
(ii) AVANIR shall have the first right, using in-house or
outside legal counsel selected at AVANIR's sole discretion, to prepare, file,
prosecute, maintain and extend patent applications and patents concerning all
such inventions and discoveries related to PRODUCT owned in whole by AVANIR, for
which AVANIR shall bear the costs. AVANIR shall solicit SB's advice and review
of the nature and text of such patent applications and important prosecution
matters related thereto in reasonably sufficient time prior to filing thereof,
and AVANIR shall take into account SB's reasonable comments related thereto.
17
<PAGE> 19
CONFIDENTIAL TREATMENT REQUESTED
(iii) If SB, prior or subsequent to filing certain patent
applications on any inventions or discoveries which are owned in part by AVANIR,
elects not to file, prosecute, maintain or extend such patent applications or
ensuing patents or certain claims encompassed by such patent applications or
ensuing patents in any country of the TERRITORY, SB shall give AVANIR notice
thereof within a reasonable period prior to allowing such patent applications or
patents or such certain claims encompassed by such patent applications or
patents to lapse or become abandoned or unenforceable, and AVANIR shall
thereafter have the right, at its sole expense, to prepare, file, prosecute and
maintain patent applications and patents or divisional applications related to
such certain claims encompassed by such patent applications or patents
concerning all such inventions and discoveries in countries of its choice
throughout the world.
(iv) If AVANIR, prior or subsequent to filing certain
patent applications on any inventions or discoveries which are owned in whole by
AVANIR, elects not to file, prosecute, maintain or extend such patent
applications or ensuing patents or certain claims encompassed by such patent
applications or ensuing patents in any country of the TERRITORY, AVANIR shall
give SB notice thereof within a reasonable period prior to allowing such patent
applications or patents or such certain claims encompassed by such patent
applications or patents to lapse or become abandoned or unenforceable, and SB
shall thereafter have the right, at its sole expense but subject to the terms of
Paragraph 3.07, to prepare, file, prosecute and maintain patent applications and
patents or divisional applications related to such certain claims encompassed by
such patent applications or patents concerning all such inventions and
discoveries in countries of its choice throughout the world.
(v) The party filing patent applications for jointly owned
inventions and discoveries shall do so in the name of and on behalf of both SB
and AVANIR. Each of AVANIR and SB shall hold all information it presently knows
or acquires under this Paragraph which is related to all such patents and patent
applications as confidential subject to the provisions of Article 6.
7.03 AVANIR warrants and represents that it has disclosed to SB the
complete texts of all patent applications filed by AVANIR as of the EFFECTIVE
DATE which relate to
18
<PAGE> 20
CONFIDENTIAL TREATMENT REQUESTED
PRODUCT in the FIELD and in the TERRITORY as well as all information received as
of the EFFECTIVE DATE concerning the institution or possible institution of any
interference, opposition, re-examination, reissue, revocation, nullification or
any official proceeding involving a PATENT anywhere in the TERRITORY. AVANIR
further warrants and represents that it will disclose to SB the complete texts
of all patent applications in the FIELD and in the TERRITORY filed by AVANIR
after the EFFECTIVE DATE which relate to PRODUCT in the TERRITORY as well as all
information received after the EFFECTIVE DATE concerning the institution or
possible institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any official proceeding involving a PATENT anywhere
in the TERRITORY. In addition to SB's rights under Paragraph 7.02, SB shall have
the right to review all such pending applications and other proceedings and make
recommendations to AVANIR concerning them and their conduct. AVANIR agrees to
keep SB promptly and fully informed of the course of patent prosecution or other
proceedings including by providing SB with copies of substantive communications,
search reports and third party observations submitted to or received from patent
offices throughout the TERRITORY. SB shall provide such patent consultation to
AVANIR at no cost to AVANIR. SB shall hold all information disclosed to it under
this section as confidential subject to the provisions of Article 6.
7.04 SB shall have the right, but not the obligation, to assume
responsibility for any PATENT or any part of a PATENT which AVANIR intends to
abandon or otherwise cause or allow to be forfeited. AVANIR shall give SB
reasonable written notice prior to abandonment or other forfeiture of any PATENT
or any part of a PATENT so as to permit SB to exercise its rights under this
Paragraph.
7.05 In the event of the institution of any suit by a THIRD PARTY
against AVANIR, SB or its AFFILIATES, its or their PERMITTED SUBLICENSEES or
distributors for patent infringement involving the manufacture, use, sale,
distribution or marketing of PRODUCT anywhere in the TERRITORY, the party sued
shall promptly notify the other party in writing. SB shall have the right, but
not the obligation, to defend such suit at its own expense. AVANIR
19
<PAGE> 21
CONFIDENTIAL TREATMENT REQUESTED
and SB shall provide reasonable assistance to one another and reasonably
cooperate in any such litigation at the other's request without expense to the
requesting party.
7.06 In the event that AVANIR or SB becomes aware of actual or
threatened infringement of a PATENT, that party shall promptly notify the other
party in writing. SB shall have the first right, but not the obligation, to
bring, at its own expense, an infringement action against any THIRD PARTY claim
in the FIELD in the TERRITORY and to use AVANIR's name in connection therewith
and to name AVANIR as a party thereto. If SB does not commence a particular
infringement action within ninety (90) days of receipt of the notice of
infringement, then AVANIR, after notifying SB in writing, shall be entitled to
bring such infringement action at its own expense. The party conducting such
action shall have full control over its conduct, including settlement thereof
subject to Paragraph 7.08. In any event, AVANIR and SB shall provide reasonable
assistance to one another and shall reasonably cooperate in any such litigation
at the other's request without expense to the requesting party. If SB becomes
aware of any suit or proceeding in a court or before a governmental authority by
any third party challenging the validity or enforceability of any PATENT, SB
shall inform AVANIR with respect thereto and offer AVANIR the right, at its sole
discretion and expense, to defend such suit or proceeding in a court or before a
governmental authority. In addition, SB agrees, upon reasonable notice, to
cooperate with and, to the extent necessary or desirable by AVANIR and at
AVANIR's expense, participate in any suit or proceeding with respect thereto.
7.07 AVANIR and SB shall recover their respective actual out-of-pocket
expenses, or equitable proportions thereof, associated with any litigation or
settlement thereof from any recovery made by any party. Any excess amount
attributable to infringement of any PATENT claim in the FIELD and in the
TERRITORY shall be shared by the parties and distributed proportionately between
SB and AVANIR (calculated on the basis of the parties' respective financial
interest in the sales of PRODUCT that were the subject of the litigation had
such sales been made by SB, its AFFILIATES or its PERMITTED SUBLICENSEES under
this AGREEMENT), provided in no event shall AVANIR's share of the excess amount
exceed the royalties which would otherwise be due AVANIR for the sales of
PRODUCT that were the
20
<PAGE> 22
CONFIDENTIAL TREATMENT REQUESTED
subject of the litigation had such sales been made by SB, its AFFILIATES or its
or their PERMITTED SUBLICENSEES under this AGREEMENT. Further, any excess amount
attributable to an infringement of any PATENT claim outside the FIELD or
TERRITORY will a) belong to AVANIR in the event the relevant litigation and / or
settlement was undertaken solely at AVANIR's risk and expense; or, b) be shared
equally between AVANIR and SB in the event that the relevant litigation and / or
settlement was undertaken solely at SB's risk and expense; or, ***
7.08 The parties shall keep one another informed of the status of and of
their respective activities regarding any litigation or settlement thereof
concerning PRODUCT, provided however that no settlement or consent judgment or
other voluntary final disposition of any suit defended or action brought by a
party pursuant to this Article 7 may be entered into without the consent of the
other party if such settlement would require the other party to be subject to an
injunction or to make a monetary payment or would otherwise adversely affect the
other party's rights under this AGREEMENT or the validity, scope or
enforceability of the PATENTS.
7.09 AVANIR shall have the right within sixty (60) days of OTC Approval
but not the obligation to seek extensions of the terms of PATENTS. At AVANIR's
request, SB shall provide reasonable assistance therefor to AVANIR or shall
diligently seek to obtain such extensions, in either event, at AVANIR's expense.
8. TRADEMARKS
8.01 SB shall be responsible for the selection of all trademarks which
it employs in connection with PRODUCT in the TERRITORY. AVANIR shall assign to
SB free of charge the worldwide rights, title and interest in and to the
trademarks *** SB and AVANIR agree that AVANIR will, at SB's expense, promptly
abandon its application for the trademark *** in the TERRITORY and, in the event
that such abandonment has not been effected, AVANIR will promptly assign to SB,
at SB's request, all right, title and interest in and to the trademark *** in
the TERRITORY, such assignment to be affected using the form assignment set out
in Appendix
21
<PAGE> 23
CONFIDENTIAL TREATMENT REQUESTED
D. AVANIR shall assist SB, at SB's expense and request, in the prosecution and
registration of the assigned trademarks.
8.02 AVANIR shall cooperate with and assist SB (at SB's expense) in
recording such trademark assignments at the appropriate trademarks offices and
in effecting a prompt transfer to SB of such domain names as are associated with
the trademarks with the relevant THIRD PARTY internet service provider.
9. STATEMENTS AND REMITTANCES
9.01 SB shall keep and require its AFFILIATES and PERMITTED SUBLICENSEES
to keep complete and accurate records of all sales of PRODUCT under the licenses
granted herein. AVANIR shall have the right, at AVANIR's expense, through an
independent certified public accountant or like person reasonably acceptable to
SB, to examine such records during regular business hours during the life of
this AGREEMENT and for six (6) months after its termination; provided, however,
that such examination shall not take place more often than once a year and shall
not cover such records for more than the preceding two (2) years and provided
further that such accountant shall report to AVANIR only as to the accuracy of
the royalty statements and payments, any applicable litigation or patent
maintenance expenses, and the expenditures set forth on Appendix C. AVANIR shall
bear the full cost and expense of any such audit unless a discrepancy in excess
of 5% in favor of SB for any quarter is discovered, in which event, SB shall
make AVANIR whole against such *** and will reimburse AVANIR against the cost
incurred in engaging such an independent certified public accountant or like
person to carry out the audit.
9.02 Within thirty (30) days after the close of each calendar quarter,
SB shall provide a true accounting of all PRODUCT sold by SB, its AFFILIATES and
PERMITTED SUBLICENSEES during such calendar quarter. Such accounting shall show
sales on a country-by-country basis. Simultaneously with the submission of the
accounting, SB shall pay to AVANIR all the royalties due to AVANIR hereunder,
and shall submit to AVANIR, together
22
<PAGE> 24
CONFIDENTIAL TREATMENT REQUESTED
with each such royalty payment, a written royalty statement describing the
calculation of royalties and applicable exchange rates.
9.03 All royalties or milestones due under this AGREEMENT shall be
payable in US Dollars.
***
9.05 Monetary conversion from the currency of a foreign country, in
which PRODUCT is sold, into U.S. Dollars shall be calculated at the actual
average rates of exchange for the pertinent quarter as used by SB in producing
its quarterly accounts, as confirmed by SB's auditors, and provided such rates
of exchange are reasonably consistent with published rates for the same time
periods.
10. TERM AND TERMINATION
10.01 This AGREEMENT shall become effective on the EFFECTIVE DATE.
Patent Royalty obligations under Paragraph 3.02 in each country of the TERRITORY
shall expire in accordance with the terms of Paragraph 3.04. Expiration of SB's
Patent Royalty obligations under Paragraph 3.04 shall not preclude SB from
continuing to market such PRODUCT and to use KNOW-HOW in such country so long as
SB continues to pay the Non-Patent Royalties under Paragraph 3.02 provided that
no further Non-Patent Royalties will be payable by SB to AVANIR after the
expiration of this AGREEMENT. ***
The expiration of this AGREEMENT shall result in a fully paid up license
of PATENTS and KNOW HOW for the benefit of SB.
10.02 ***
10.03 If either party fails or neglects to perform covenants or
provisions of this AGREEMENT and if such default is not corrected within sixty
(60) days after receiving written notice from the other party, or within ten
(10) business days of receiving written notice from AVANIR in the case of SB's
payment obligations under this AGREEMENT, with respect to
23
<PAGE> 25
CONFIDENTIAL TREATMENT REQUESTED
such default, such other party shall have the right to terminate this AGREEMENT
by giving written notice to the party in default provided the notice of
termination is given within six (6) months of the default and prior to
correction of the default.
10.04 SB may terminate this AGREEMENT on a country by country basis, or
in its entirety a) by giving AVANIR at least sixty (60) days written notice
thereof at any time before the date of first commercial sale of PRODUCT in such
country based on a reasonable determination by SB, using the same standards SB
would use in assessing whether or not to continue development of a product of
its own making, that the patent, medical/scientific, technical, regulatory or
commercial profile of PRODUCT does not justify continued development of PRODUCT
in such country, or b) forthwith on notice of termination being served on AVANIR
by SB in the event of the occurrence of a FORCE MAJEURE EVENT prior to OTC
Launch ( as defined in Paragraph 3.01) of PRODUCT. After the date of first
commercial sale of PRODUCT, SB may terminate this AGREEMENT on a country by
country basis, or in its entirety, by giving AVANIR at least one hundred eighty
(180) days prior written notice thereof based on a reasonable determination by
SB, using the same standards SB would use in assessing whether or not to
continue development of a product of its own making, that the patent,
medical/scientific, technical, regulatory or commercial profile of PRODUCT does
not justify continued development of PRODUCT in such country. Termination of
this AGREEMENT in respect of the United States shall constitute a termination of
this AGREEMENT in its entirety.
10.05 Either party may terminate this AGREEMENT if, at any time, the
other party shall file in any court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or
trustee of the party or of its assets, or if the other party proposes a written
agreement of composition or extension of its debts, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed with sixty (60) days after
the filing thereof, or if the other party shall propose or
24
<PAGE> 26
CONFIDENTIAL TREATMENT REQUESTED
be a party to any dissolution or liquidation, or if the other party shall make
an assignment for the benefit of creditors.
10.06 Notwithstanding the bankruptcy of AVANIR, or the impairment of
performance by AVANIR of its obligations under this AGREEMENT as a result of
bankruptcy or insolvency of AVANIR, SB shall be entitled to retain the licenses
granted herein, subject to AVANIR's rights to terminate this AGREEMENT for
reasons other than bankruptcy or insolvency as expressly provided in this
AGREEMENT.
10.07 All rights and distribution rights granted under or pursuant to
this AGREEMENT by AVANIR to SB are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to
"intellectual property" as defined under Section 101(52) of the U.S. Bankruptcy
Code. The parties agree that SB, as a licensee of such rights under this
AGREEMENT, shall retain and may fully exercise all of its rights and elections
under the U.S. Bankruptcy Code, subject to performance by SB of its preexisting
obligations under this AGREEMENT. The parties further agree that, in the event
of the commencement of a bankruptcy proceeding by or against AVANIR under the
U.S. Bankruptcy Code, SB shall be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all
embodiments of such intellectual property, and same, if not already in its
possession, shall be promptly delivered to SB (a) upon any such commencement of
a bankruptcy proceeding upon written request therefor by SB, unless AVANIR
elects to continue to perform all of its obligations under this AGREEMENT, or
(b) if not delivered under (a) above, upon the rejection of this AGREEMENT by or
on behalf of AVANIR upon written request therefor by SB, provided, however, that
upon AVANIR's (or its successor's) written notification to SB that it is again
willing and able to perform all of its obligations under this AGREEMENT, SB
shall promptly return all such tangible materials to AVANIR, but only to the
extent that SB does not require continued access to such materials to enable SB
to perform its obligations under this AGREEMENT.
11. RIGHTS AND DUTIES UPON TERMINATION
25
<PAGE> 27
CONFIDENTIAL TREATMENT REQUESTED
11.01 Upon termination of this AGREEMENT, AVANIR shall have the right to
retain any sums already paid by SB hereunder, and SB shall pay all sums accrued
hereunder which are then due (including all royalties and milestones that have
accrued as of the date of termination). Notwithstanding the foregoing, in the
event that SB terminates this AGREEMENT under Paragraph 10.04 (b), then SB's
obligation to make any further milestone payments will be extinguished forthwith
without further claim from or liability to AVANIR, including with regard to any
milestone payments that have become due and payable under Paragraph 3.01 but in
respect of which SB has not made payment to AVANIR as at the date of SB's notice
of termination.
11.02 Upon termination of this AGREEMENT in its entirety or with respect
to PRODUCT in any country under Paragraphs 10.03 (except in the case of SB's
breach), 10.04, 10.06 SB shall notify AVANIR of the amount of PRODUCT SB, its
AFFILIATES, PERMITTED SUBLICENSEES and distributors then have on hand, the sale
of which would, but for the termination, be subject to royalty, and SB, its
AFFILIATES, PERMITTED SUBLICENSEES and distributors shall thereupon be permitted
to sell that amount of PRODUCT within an additional period of 180 days (unless
otherwise agreed by SB and AVANIR) of such termination provided that SB shall
pay the royalty thereon at the time herein provided for such an additional
period.
11.03 Termination of this AGREEMENT shall terminate all outstanding
licenses, obligations and liabilities between the parties arising from this
AGREEMENT except those described in Paragraphs 1, 6.02, 6.04, 7.07, 9, 11,
12.05, 12.06 and 12.08, and any other obligations otherwise provided by this
AGREEMENT which have accrued. In addition, any other provision required to
interpret and enforce the parties' rights and obligations under this AGREEMENT
shall also survive, but only to the extent required for the full observation and
performance of this AGREEMENT.
11.04 Termination of the AGREEMENT in accordance with the provisions
hereof shall not limit remedies which may be otherwise available in law or
equity.
26
<PAGE> 28
CONFIDENTIAL TREATMENT REQUESTED
11.05 In the event of any termination of this AGREEMENT in its entirety
(a) SB shall within three days prepare and send an executed letter to FDA or
Health Canada authorizing the transfer of the PRODUCT marketing application to
AVANIR, and SB shall also transfer to AVANIR all regulatory documents, a
chronology of discussions with FDA or Health Canada, and other information
necessary to maintain compliance with the US, Canadian, and any other regulatory
authorities; (b) SB will continue to provide AVANIR with assistance ensuring the
orderly transition of the PRODUCT and its corresponding regulatory approvals to
AVANIR; (c) SB will transfer all manufacturing information (in so far as such
information is within SB's control and in so far as SB is legally able to
transfer the information) to AVANIR and will continue to manufacture AVANIR's or
its licensees' requirements of the PRODUCT until such time as a substitute
manufacturing source has been approved by the FDA and on such terms as shall be
agreed by the parties negotiating in good faith ***
12. WARRANTIES AND REPRESENTATIONS
12.01 AVANIR warrants and represents that it owns the entire right,
title and interest in the PATENTS listed in Appendix A, or filed by or on behalf
of AVANIR pursuant to Section 7, and the KNOW-HOW provided to SB under this
AGREEMENT, and that it otherwise has the right to enter into this AGREEMENT.
AVANIR further warrants and represents that there is nothing in any THIRD PARTY
agreement AVANIR has entered into as of the EFFECTIVE DATE which, in any way,
will limit AVANIR's ability to perform all of the obligations undertaken by
AVANIR hereunder, and that it will not enter into any AGREEMENT after the
EFFECTIVE DATE under which AVANIR would incur any such limitations.
12.02 Nothing in this AGREEMENT shall be construed as a warranty that
PATENTS are valid or enforceable as of the EFFECTIVE DATE, or that they will be
so during the term of this AGREEMENT. AVANIR hereby warrants and represents that
it has no present knowledge from which it can be inferred that PATENTS are
invalid or that their exercise would infringe patent rights of THIRD PARTIES.
AVANIR further warrants and represents that it has no present knowledge from
which it can be inferred that the process of manufacturing PRODUCT,
27
<PAGE> 29
CONFIDENTIAL TREATMENT REQUESTED
and all intermediates of such process, will infringe patent rights of THIRD
PARTIES in both the country in which the PRODUCT is produced as well as all
countries of the TERRITORY.
12.03 AVANIR warrants and represents that it has not, up through and
including the EFFECTIVE DATE, omitted to furnish SB with any information in its
possession concerning PRODUCT or the transactions contemplated by this
AGREEMENT, which has been requested by SB pursuant to this AGREEMENT or which so
far as AVANIR is aware may affect SB's decision to enter into this AGREEMENT and
to undertake the commitments and obligations set forth herein.
12.04 AVANIR warrants and represents that it has no present knowledge of
the existence of any pre-clinical or clinical data or information concerning the
PRODUCT which it has not provided to SB prior to the EFFECTIVE DATE which
suggests that there may exist quality, toxicity, safety and/or efficacy concerns
which may materially impair the utility and/or safety of the PRODUCT.
12.05 SB shall defend, indemnify and hold harmless AVANIR, its
AFFILIATES and its and their respective officers, directors, employees, agents,
successors and assigns from any loss, damage, or liability, including reasonable
attorney's fees, resulting from any claim, complaint, suit, proceeding or cause
of action against any of them alleging physical or other injury, including
death, arising out of the administration, utilization and/or ingestion of
PRODUCT manufactured, sold, supplied or otherwise provided to the injured party
directly or indirectly by SB, its AFFILIATES or its PERMITTED SUBLICENSEES
provided:
(a) SB shall not be obligated under this Paragraph if it is shown
by evidence acceptable in a court of law having jurisdiction over the subject
matter and meeting the appropriate degree of proof for such action, that the
injury was the result of the negligence or willful misconduct of any employee or
agent of AVANIR or the breach of any warranty or representation made by AVANIR
in this AGREEMENT;
28
<PAGE> 30
CONFIDENTIAL TREATMENT REQUESTED
(b) SB shall have no obligation under this Paragraph unless
AVANIR (i) gives SB prompt written notice of any claim or lawsuit or other
action for which it seeks to be indemnified under this AGREEMENT, (ii) SB is
granted full authority and control over the defense, including settlement,
against such claim or lawsuit or other action, and (iii) AVANIR cooperates fully
with SB and its agents in defense of the claims or lawsuit or other action; and
(c) AVANIR shall have the right to participate in the defense of
any such claim, complaint, suit, proceeding or cause of action referred to in
this Paragraph utilizing attorneys of its choice, at its own expense, provided,
however, that SB shall have full authority and control to handle any such claim,
complaint, suit, proceeding or cause of action, including any settlement or
other disposition thereof, for which AVANIR seeks indemnification under this
Paragraph.
12.06 AVANIR shall defend, indemnify and hold harmless SB, its
AFFILIATES, and its and their officers, directors, employees, agents,
successors, PERMITTED SUBLICENSEES and assigns from any loss, damage, or
liability, including reasonable attorney's fees, resulting from any claim,
complaint, suit, proceeding or cause of action against any of them alleging
physical or other injury, including death, rising out of the administration,
utilization and/or ingestion of PRODUCT manufactured, sold, supplied or
otherwise provided to the injured party by AVANIR, its AFFILIATES or any of
AVANIR's sublicensees provided:
(a) AVANIR shall not be obligated under this Paragraph if it is
shown by evidence acceptable in a court of law having jurisdiction over the
subject matter and meeting the appropriate degree of proof for such action, that
the injury was the result of the negligence or willful misconduct of any
employee or agent of SB or the breach of any warranty or representation made by
SB in this AGREEMENT;
(b) AVANIR shall have no obligation under this Paragraph unless
SB (i) gives AVANIR prompt written notice of any claim or lawsuit or other
action for which it seeks to be indemnified under this AGREEMENT, (ii) AVANIR is
granted full authority and control over the defense, including settlement,
against such claim or lawsuit or other action, and (iii) SB
29
<PAGE> 31
CONFIDENTIAL TREATMENT REQUESTED
cooperates fully with AVANIR and its agents in defense of the claims or lawsuit
or other action; and
(c) SB shall have the right to participate in the defense of any
such claim, complaint, suit, proceeding or cause of action referred to in this
Paragraph utilizing attorneys of its choice, at its own expense, provided,
however, that AVANIR shall have full authority and control to handle any such
claim, complaint, suit, proceeding or cause of action, including any settlement
or other disposition thereof, for which SB seeks indemnification under this
Paragraph.
12.07 For the term of this AGREEMENT and for a period of five (5) years
after the expiration of this AGREEMENT or earlier termination, each party shall
obtain and/or maintain, respectively, at its sole cost and expense, product
liability insurance in amounts, respectively, which are reasonable and customary
in the U.S. pharmaceutical industry considering the respective size and
activities of the two parties. Such product liability insurance shall insure
against all liability, including liability for personal injury, physical injury
and property damage. Each party shall provide written proof of the existence of
such insurance to the other party upon request.
12.08 SB warrants and represents that SB shall have, at the time of the
NDA transfer from AVANIR to SB, the in-house expertise to comply in all material
respects with FDA requirements and to maintain this compliance throughout the
license term. Each party agrees to comply with all applicable laws and
governmental regulations and requirements.
13. FORCE MAJEURE
13.01 If the performance of any part of this AGREEMENT by either party,
or of any obligation under this AGREEMENT, is prevented, restricted, interfered
with or delayed by reason of a FORCE MAJEURE EVENT unless conclusive evidence to
the contrary is provided, the party so affected shall, upon giving written
notice to the other party, be excused from such performance to the extent of
such prevention, restriction, interference or delay, provided that the affected
party shall use its reasonable efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever
such causes are removed.
30
<PAGE> 32
CONFIDENTIAL TREATMENT REQUESTED
When such circumstances arise, the parties shall discuss what, if any,
modification of the terms of this AGREEMENT may be required in order to arrive
at an equitable solution. It is agreed that the provisions of this Paragraph
13.01 will be subject in all respects to SB's termination rights under Paragraph
10.04.
14. GOVERNING LAW AND DISPUTE RESOLUTION
14.01 This AGREEMENT shall be governed by the laws of the Commonwealth
of Pennsylvania and its form, execution, validity, construction and effect shall
be determined in accordance with the same.
14.02 Any dispute, controversy or claim arising out of or relating to
this AGREEMENT (hereinafter collectively referred to as "Dispute") shall be
attempted to be settled by the parties, in good faith, by submitting each such
Dispute to appropriate senior management representatives of each PARTY in an
effort to effect a mutually acceptable resolution thereof.
14.03 In the event no mutually acceptable resolution of such Dispute is
achieved in accordance with Paragraph 14.02 within a reasonable period of time,
then either PARTY shall be entitled to seek final settlement of such Dispute by
any administrative or judicial mechanism which may be available. In the event
that either party elects to pursue a judicial mechanism, it is agreed that
proceedings will not be commenced in the territory of Puerto Rico.
15. BULK PRODUCT AND SUPPLY
15.01 Within ten (10) days of the EFFECTIVE DATE, SB shall purchase at
cost the bulk PRODUCT owned by AVANIR provided that such bulk PRODUCT conforms
to agreed specifications *** Further and at SB's election, AVANIR shall
cooperate with SB in effecting the transfer of such purchased bulk PRODUCT from
its current storage location to a site nominated by SB.
31
<PAGE> 33
CONFIDENTIAL TREATMENT REQUESTED
***
16. WAIVER OF BREACH
16.01 The failure of either party at any time or times to require
performance of any provision hereof shall in no manner affect its rights at a
later time to enforce the same. No waiver by either party of any condition or
term in any one or more instances shall be construed as a further or continuing
waiver of such condition or term or of another condition or term.
17. SEPARABILITY
17.01 In the event any portion of this AGREEMENT shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.
17.02 If any of the terms or provisions of this AGREEMENT are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.
17.03 In the event that the terms and conditions of this AGREEMENT are
materially altered as a result of Paragraphs 17.01 or 17.02, the parties will
attempt to renegotiate the terms and conditions of this AGREEMENT to resolve any
inequities.
18. ENTIRE AGREEMENT
18.01 This AGREEMENT, entered into as of the date written above,
constitutes the entire agreement between the parties relating to the subject
matter hereof and supersedes all previous writings and understandings. No terms
or provisions of this AGREEMENT shall be varied or modified by any prior or
subsequent statement, conduct or act of either of the parties, except that the
parties may amend this AGREEMENT by written instruments specifically referring
to and executed in the same manner as this AGREEMENT.
19. NOTICES
32
<PAGE> 34
CONFIDENTIAL TREATMENT REQUESTED
19.01 Notices required or permitted under this AGREEMENT shall be in
writing and sent by prepaid registered or certified air mail or by overnight
express mail (e.g., FedEx), or by facsimile confirmed by prepaid registered or
certified air mail letter or by overnight express mail (e.g., FedEx), and shall
be deemed to have been properly served to the addressee upon receipt of such
written communication, to the following addresses of the parties:
If to AVANIR:
9393 Towne Centre Drive, Ste. 200
San Diego, California 92121
Attn: Chief Executive Officer
Facsimile: (858) 455-8059
Copy to: Heller Ehrman White & McAuliffe
4250 Executive Square, 7th Floor
La Jolla, California 92037-9103
Attn: Randall K. Broberg, Esq.
Facsimile: (858) 450-8499
If to SB: SB Pharmco Puerto Rico Inc
Road 172, Rm 9.1/Bo., Certenejas,
Cidra,
Puerto Rico 00639
Attention: General Manager
Facsimile: 809-250-3894
Copy to: SmithKline Beecham Corporation
One Franklin Plaza (Mail Code FP2360)
P.O. Box 7929
Philadelphia, Pennsylvania 19101, U.S.A.
Attention: Corporate Law-U.S.
Facsimile: 215-751-3935
20. ASSIGNMENT
20.01 This AGREEMENT and the licenses herein granted shall be binding
upon and inure to the benefit of the successors in interest of the respective
parties. Neither this AGREEMENT nor any interest hereunder shall be assignable
by either party without the written
33
<PAGE> 35
CONFIDENTIAL TREATMENT REQUESTED
consent of the other, such consent not to be unreasonably withheld or delayed;
provided, however, that either party may assign this AGREEMENT or any part of
its rights and obligations hereunder to any AFFILIATE of such assigning party or
to any corporation with which such assigning party may merge or consolidate, or
to which it may transfer all or substantially all of its assets to which this
AGREEMENT relates without obtaining the consent of the other party hereto.
21. RECORDING
21.01 SB shall have the right, at any time, to record, register, or
otherwise notify this AGREEMENT in appropriate governmental or regulatory
offices anywhere in the TERRITORY, and AVANIR shall provide reasonable
assistance to SB in effecting such recording, registering or notifying.
22. EXECUTION IN COUNTERPARTS
22.01 This AGREEMENT may be executed in any number of counterparts, each
of which shall be deemed an original but all of which together shall constitute
one and the same instrument.
34
<PAGE> 36
CONFIDENTIAL TREATMENT REQUESTED
IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this AGREEMENT as of the date first written above.
SB PHARMCO PUERTO RICO INC.
BY: /s/ JOSE L. ROSADO
------------------
NAME: Jose L. Rosado
TITLE: President and General Manager
AVANIR PHARMACEUTICALS
BY: /S/ GERALD J. YAKATAN
-----------------------
NAME: Gerald J. Yakatan
TITLE: President and Chief Executive Officer
35
<PAGE> 37
CONFIDENTIAL TREATMENT REQUESTED
LICENSE AGREEMENT
SB PHARMCO PUERTO RICO INC. - AVANIR PHARMACEUTICALS
APPENDIX A
PATENTS
<TABLE>
<CAPTION>
===========================================================================================================
Title Country Appl. No. Appl. Date Patent No. Grant Date Exp. Date
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
- -----------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------
- ------------------------- ------------ ----------- -------------- ------------ -------------- -------------
===========================================================================================================
</TABLE>
***
36
<PAGE> 38
CONFIDENTIAL TREATMENT REQUESTED
APPENDIX B
PHARMACOVIGILANCE AGREEMENT
PROCEDURE FOR EXCHANGE OF ADVERSE EVENT DATA FROM CLINICAL TRIALS AND
POSTMARKETING REPORTS
DEFINITIONS
The following definitions reflect and are consistent with FDA and International
Conference on Harmonization (ICH) regulations/guidelines.
- - ADVERSE EXPERIENCE/EVENT (AE)
The ICH has defined an AE as "any untoward medical occurrence in a
patient or clinical investigation subject administered a pharmaceutical
product and which does not necessarily have to have a causal
relationship with this treatment."
- - ADVERSE DRUG REACTION (ADR)
In the pre-approval clinical experience or in other clinical trial
experiences The ICH has defined an ADR in clinical trials as "all
noxious and unintended responses to a medical product related to any
dose". The phrase "responses to a medicinal product" means that a causal
relationship between a medicinal product and an adverse event is at
least a reasonable possibility, i.e. the relationship cannot be ruled
out.
For marketed medical products
The ICH had defined an ADR in marketed medicinal products as "a response to a
drug which is noxious and unintended and which occurs at doses normally used in
man for prophylaxis, diagnosis or therapy of disease or for modification of
physiological function."
37
<PAGE> 39
CONFIDENTIAL TREATMENT REQUESTED
- - UNEXPECTED ADR
The ICH has defined an unexpected ADR as "an adverse reaction, the
nature or severity of which is not consistent with the applicable
product information (e.g. Investigator Brochure) for an unapproved
investigational medicinal product.
This definition includes an AE/adr of which the nature, specificity, or
severity is inconsistent with the applicable product information. For an
AE/ADR from a clinical trial, the reference document shall be the
Investigator Brochure.
- - SERIOUS AE
A serious AE is any untoward medical occurrence that:
* results in death
* is life-threatening
NOTE: The term "life-threatening" in the definition of "serious"
refers to an event in which the patient was at risk of death at the
time of the event; it does not refer to an event which
hypothetically might have caused death if it were more severe.
* requires inpatient hospitalization or prolongation of existing
hospitalization
* results in persistent or significant disability/incapacity, or
* is a congenital anomaly/birth defect.
Medical and scientific judgment should be exercised in deciding whether
expedited reporting is appropriate in other situations, such as
important medical events that may not be immediately life-threatening or
result in death or hospitalization but may jeopardize the patient or may
require intervention to prevent one of the other outcomes listed in the
definition above. These should also usually be considered serious.
(Examples of such events are intensive treatment in an emergency room or
at home for allergic bronchospasm; blood dyscrasias or convulsions that
do not result in hospitalization; or development of drug dependency or
drug abuse.)
38
<PAGE> 40
CONFIDENTIAL TREATMENT REQUESTED
- - NON-SERIOUS AE
A non-serious AE is any experience which does not meet the definition of
serious as defined above.
Clinical trial experiences which are not considered "serious" include:
hospitalization for a pre-planned/elective procedure for a medical
condition present before treatment started; a pre-existing medical
condition which does not increase in severity or frequency following
treatment; or an experience which is simply a treatment failure
according to the efficacy criteria for the study.
REPORTING
- - REPORTS OF PREGNANCY
While such reports are not AEs as defined herein, reports of pregnancies
should be followed up until the outcome of the pregnancy is known.
- - MINIMUM CRITERIA FOR REPORTING
INITIAL REPORTS SHOULD BE SUBMITTED WITHIN THE AGREED TIMELINES AS LONG
AS THE FOLLOWING MINIMUM CRITERIA ARE MET:
an identifiable patient; a suspect medicinal product; an identifiable
reporting source; and an event or outcome
- - FOLLOW-UP OF CASES
The party who is the initial recipient of the AE report shall be
responsible for appropriate follow-up of that AE report and timely
transmission of relevant new information to the other party. Follow-up
information should be actively sought by the party and submitted within
the same timelines as an initial report.
POLICY
- - SB will hold the recognized worldwide safety database for PRODUCT
- - SB is responsible for regulatory reporting in the TERRITORY and AVANIR
is responsible for regulatory reporting outside of the TERRITORY.
39
<PAGE> 41
CONFIDENTIAL TREATMENT REQUESTED
- - If either party becomes aware of a safety issue they will immediately
inform the other party.
- - Each party will inform the other party of any safety related queries
from a regulatory authority.
- - This agreement will be updated periodically in response to regulatory
changes, at the request of either party.
DATA EXCHANGE
- - Data will be transferred in English by fax or electronically.
- - AVANIR is responsible for receiving and forwarding reports to and from
other AVANIR licensees (if applicable)
- - SB is responsible for receiving and forwarding reports to and from other
SB sub-licensees (if applicable)
- - SB WILL SEND AVANIR WRITTEN NOTICE OF:
* Fatal and life-threatening events which are unexpected and
considered possibly drug related by fax within 24 hours of receipt
* All other serious adverse events within 5 days
- - AVANIR WILL SEND TO SB WRITTEN NOTICE OF:
* Fatal and life-threatening events which are unexpected and
considered possibly drug related by fax within 24 hours of receipt
* All other serious adverse events within 5 days
- - LITERATURE REPORTS:
* Each party shall be responsible for scanning and processing
applicable AE reports in literature in the territory in which it
holds registration rights as set forth in this agreement.
- - REGULATORY REPORTING:
40
<PAGE> 42
CONFIDENTIAL TREATMENT REQUESTED
* Reporting of domestic or foreign cases to the local regulatory
authorities is the responsibility of the local registration holder.
* SB and AVANIR shall be responsible for reporting of AE cases to the
local regulatory authorities in those countries where they are
respectably the local registration holder.
PHARMACOVIGILANCE CONTACTS IN EACH PARTY:
<TABLE>
<CAPTION>
FOR SB: CONTACT ADDRESS AND NUMBERS
- --------------- ----------------------------------------- -----------------------------------
<S> <C> <C>
Primary: Reinerio A. Deza, MD SmithKline Beecham Consumer
Director, NA Medical Affairs Healthcare
& Safety 100 Beecham Drive
Pittsburgh, PA 15205 USA
SmithKline Beecham Consumer Tel: (412) 928-1085
Healthcare Fax: (412) 928-6958
E-mail:
[email protected]
UK Contact: Bryan Shapiro, MD SBCH Research Centre
Assoc. Dir., EU Medical Services St. George's Avenue
Weybridge
Surrey KT13 ODE, UK
Tel. +44 932 82 2223
Fax +44 932 82 2156
</TABLE>
FOR AVANIR CONTACT ADDRESS AND NUMBERS:
41
<PAGE> 43
CONFIDENTIAL TREATMENT REQUESTED
APPENDIX C
***
42
<PAGE> 44
CONFIDENTIAL TREATMENT REQUESTED
APPENDIX D: FORM TRADEMARK ASSIGNMENT
ASSIGNMENT
WHEREAS, AVANIR PHARMACEUTICALS (HEREINAFTER "AVANIR"), A CALIFORNIA CORPORATION
WITH A BUSINESS ADDRESS OF 9393 TOWN CENTRE DRIVE, SUITE 200, SAN DIEGO,
CALIFORNIA 92121, IS THE OWNER OF THE TRADEMARKS AND TRADEMARK APPLICATIONS FOR
***; AND
WHEREAS, SB PHARMCO PUERTO RICO INC. (HEREINAFTER "SB"), A COMPANY OF THE
TERRITORY OF PUERTO RICO WITH A BUSINESS ADDRESS OF ROAD 172, RM 9.1/BO.,
CERTENEJAS, CIDRA PUERTO RICO 00639, THE SUCCESSOR OF THE PORTION OF THE ONGOING
AND EXISTING BUSINESS OF AVANIR TO WHICH THE MARKS PERTAIN, IS DESIROUS OF
ACQUIRING SAID TRADEMARKS AND THE PENDING INTENT TO USE APPLICATIONS THEREFOR;
NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, THE RECEIPT OF WHICH IS
HEREBY ACKNOWLEDGED, AVANIR DOES HEREBY ASSIGN TO SB ALL WORLDWIDE RIGHTS, TITLE
AND INTEREST IN AND TO THE TRADEMARKS *** AND THE INTENT TO USE APPLICATIONS FOR
THE MARKS AS PART OF THE PORTION OF THE BUSINESS TO WHICH THE MARKS PERTAIN,
TOGETHER WITH THE GOODWILL OF THE BUSINESS SYMBOLIZED THEREBY.
AVANIR PHARMACEUTICALS
BY:___________________________
TITLE:________________________
DATE:_________________________
43
<PAGE> 45
CONFIDENTIAL TREATMENT REQUESTED
APPENDIX E: DOMAIN NAMES
***
44
<PAGE> 1
EXHIBIT 99.1
NEWS RELEASE
FOR IMMEDIATE RELEASE
Contacts:
AVANIR Pharmaceuticals: SmithKline Beecham
J. David Hansen Media: Nancy Lovre
858/ 410-2656 412/ 928-1105
Investor Relations: Patrice Saxon Investor Relations: Richard Williams
858/ 410-2660 215/ 751-7002
SMITHKLINE BEECHAM TO MARKET AVANIR'S OTC DOCOSANOL CREAM
UPFRONT LICENSING FEES AND MILESTONE PAYMENTS SET
San Diego, April 3, 2000 - AVANIR Pharmaceuticals (OTC BB: AVNR)
announced today that it has signed an agreement with SmithKline Beecham (NYSE:
SBH) to give SmithKline the rights to market AVANIR's docosanol 10% cream as a
treatment for cold sores. The exclusive agreement covers the United States and
Canada.
Under terms of the agreement, SmithKline Beecham Consumer Healthcare
will be responsible for all sales and marketing activities, as well as
manufacturing and distribution of the product. The terms of the agreement
provide for AVANIR to receive an upfront licensing payment as well as milestone
payments up to $25 million tied to product launch and sales performance criteria
at intervals up to one year from product launch. AVANIR will also receive
royalties on product sales. Additionally, SmithKline Beecham has the option to
negotiate for rights to market in other countries not currently covered outside
the U.S. and Canada.
The product will be sold in the over-the-counter market. Docosanol 10%
is a topical cream discovered and developed by AVANIR Pharmaceuticals. While
currently under review by the U.S. Food and Drug Administration, if approved,
docosanol will be the first OTC product in the cold sore treatment category with
FDA approval.
"SmithKline Beecham has the expertise and requisite knowledge of the OTC
market to maximize AVANIR 's return on our research investment in docosanol,"
said Gerald J. Yakatan, Ph.D., AVANIR 's chief executive officer and president.
"We look forward to the launch of our lead product and bringing future products
to the marketplace to implement our strategy of becoming a specialty
pharmaceutical company."
"SmithKline Beecham is pleased to be working with AVANIR," said George
Quesnelle, Vice President of Medical Marketing, SmithKline Beecham Consumer
Healthcare. "We look to
<PAGE> 2
licensing as a source of growth for our company, and we will put our full effort
behind this partnership. Docosanol will be the first OTC cold sore treatment
that provides true therapeutic benefit for the more than 40 million people who
suffer from recurrent cold sores."
AVANIR Pharmaceuticals, based in San Diego, California, is a specialty
pharmaceutical company that identifies, acquires and commercializes therapeutic
compounds through discovery and in-licensing. Visit www.avanir.com for more
information.
SmithKline Beecham (NYSE: SBH) - one of the world's leading health-care
companies - discovers, develops, manufactures and markets pharmaceuticals,
vaccines, over-the-counter medicines and health-related consumer products. For
company information, visit SmithKline Beecham on the World Wide Web at
www.sb.com.
###
The information contained in this press release, including any forward looking
statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development and clinical trials.
Regulatory agency approval and market acceptance for docosanol and other drug
products is unpredictable and substantially outside of the influence and/or
control of the Company.
